Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
 |
|
|
||||||||||||||||||||||||||||||||||||||||||
| Title: | In vitro-derived genetically altered human neutrophil precursor cells and methods for administering the same |
| Inventors: | Bender, James G.; Lindenhurst, IL, USA Maples, Phillip B.; Waukegan, IL, USA Smith, Stephen; Arlington Heights, IL, USA Unverzagt, Kristen L.; Palatine, IL, USA Van Epps, Dennis E.; Cary, IL, USA |
| Summary: | Described herein are compositions containing human neutrophil precursor cells with a high content of myeloblasts and pro-myelocytes, methods and uses thereof. The invention relates to genetically altered human neutrophil precursor cells with a cellular component containing approximately 16% human myeloblasts and promyelocytes which have been derived from neutrophil progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than approximately 5% colony forming units (CFU) of at least 50 cells. Multiple embodiments of the invention are provided. Therapeutic applications in the treatment of genetic or acquired neutropenia are included. |
| Abstract: | A composition comprising genetically altered human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% human myeloblasts and promyelocytes, which have been derived from neutrophil progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than about 5% colony forming units (CFU) of at least about 50 cells is provided. An alternative composition comprising genetically altered human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% CD15+CD11b- cells and less than about 5% colony forming units (CFU) of at least about 50 cells also is provided, wherein at least about 60% of the CD15+CD11b- cells are myeloblasts and promyelocytes. |
| US Patent Website: | Click Here for Full Text of Patent |
| Title Number: | US6146623 |
| Application Number: | US1995000485579 |
| Date Filed: | 07/06/1995 |
| Date Published: | 14/11/2000 |
| Assignee: | Nexell Therapeutics Inc., Irvine, CA, USA |